Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors

BackgroundBruton tyrosine kinase (Btk) plays an important role in B-cell development, differentiation, and signaling. It is also found be in involved in male immunodeficiency disease such as X-linked agammaglobulinemia (XLA). Btk is considered as a potential therapeutic target for treating autoimmune diseases and hematological malignancies.ResultsIn this work, a combined molecular modeling study was performed on a series of thieno [3,2-c] pyridine-4-amine derivatives as Btk inhibitors. Receptor-guided COMFA (q2 = 0.574, NOC = 3, r2 = 0.924) and COMSIA (q2 = 0.646, NOC = 6, r2 = 0.971) models were generated based on the docked conformation of the most active compound 26. All the developed models were tested for robustness using various validation techniques. Furthermore, a 5-ns molecular dynamics (MD) simulation and binding free energy calculations were carried out to determine the binding modes of the inhibitors and to identify crucial interacting residues. The rationality and stability of molecular docking and 3D-QSAR results were validated by MD simulation. The binding free energies calculated by the MM/PBSA method showed the importance of the van der Waals interaction.ConclusionsA good correlation between the MD results, docking studies, and the contour map analysis were observed. The study has identified the key amino acid residues in Btk binding pocket. The results from this study can provide some insights into the development of potent, novel Btk inhibitors.

[1]  Seung Joo Cho,et al.  3D QSAR modeling study on 7-aminofuro [2,3-c] pyridine derivatives as TAK1 inhibitors using CoMFA and COMSIA , 2014, Medicinal Chemistry Research.

[2]  Ruisheng Zhang,et al.  Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, Bioorganic & medicinal chemistry.

[3]  I. Weissman,et al.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D J Rawlings,et al.  In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[6]  Chang-Guo Zhan,et al.  Combined 3D-QSAR Modeling and Molecular Docking Study on Indolinone Derivatives as Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase-1 , 2008, J. Chem. Inf. Model..

[7]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[8]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[9]  J. Cohen,et al.  Mechanisms of Lymphocyte Activation and Immune Regulation V , 1994, Advances in Experimental Medicine and Biology.

[10]  Berk Hess,et al.  P-LINCS:  A Parallel Linear Constraint Solver for Molecular Simulation. , 2008, Journal of chemical theory and computation.

[11]  Paola Gramatica,et al.  Real External Predictivity of QSAR Models. Part 2. New Intercomparable Thresholds for Different Validation Criteria and the Need for Scatter Plot Inspection , 2012, J. Chem. Inf. Model..

[12]  D. Vetrie,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[13]  Fatih M. Uckun,et al.  Bruton’s Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex* , 1999, The Journal of Biological Chemistry.

[14]  O. Witte,et al.  X-linked agammaglobulinemia and Bruton's tyrosine kinase. , 1994, Advances in experimental medicine and biology.

[15]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[16]  Yan Wang,et al.  Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. , 2014, Journal of medicinal chemistry.

[17]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[18]  L. Silvian,et al.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.

[19]  Kunal Roy,et al.  Some case studies on application of “rm2” metrics for judging quality of quantitative structure–activity relationship predictions: Emphasis on scaling of response data , 2013, J. Comput. Chem..

[20]  Christine Kinnon,et al.  Pillars Article: The Gene Involved in X-linked Agammaglobulinaemia Is a Member of the Src Family of Protein-Tyrosine Kinases. Nature. 1993. 361: 226–233 , 2012 .

[21]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[22]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[23]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[24]  F. Uckun,et al.  Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. , 1998, Biochemical pharmacology.

[25]  Zheng Yang,et al.  Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2). , 2015, Bioorganic & medicinal chemistry letters.

[26]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[27]  Paola Gramatica,et al.  Real External Predictivity of QSAR Models: How To Evaluate It? Comparison of Different Validation Criteria and Proposal of Using the Concordance Correlation Coefficient , 2011, J. Chem. Inf. Model..

[28]  Narayanan Eswar,et al.  Protein structure modeling with MODELLER. , 2008, Methods in molecular biology.

[29]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[30]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[31]  D J Rawlings,et al.  Regulation of Btk function by a major autophosphorylation site within the SH3 domain. , 1996, Immunity.

[32]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[33]  Adrian Wiestner,et al.  Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D J Rawlings,et al.  Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Kinet,et al.  Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases , 1996, Science.

[36]  Seung Joo Cho,et al.  Structural insights into the ligand-binding hot spots of APEX1: an in silico analysis , 2015, Medicinal Chemistry Research.

[37]  Seung Joo Cho,et al.  Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach , 2016, Archives of pharmacal research.

[38]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[39]  W. Paul,et al.  Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. , 1993, Science.

[40]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[41]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[42]  O. Witte,et al.  Bruton's Tyrosine Kinase is a Key Regulator in B‐Cell Development , 1994, Immunological reviews.

[43]  Wei Huang,et al.  Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2015, Bioorganic & medicinal chemistry.

[44]  Wei Huang,et al.  Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors. , 2015, Bioorganic & medicinal chemistry.

[45]  H. Ochs,et al.  Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. , 2000, Blood.

[46]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[47]  Wim F Vranken,et al.  ACPYPE - AnteChamber PYthon Parser interfacE , 2012, BMC Research Notes.

[48]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[49]  Seung Joo Cho,et al.  Molecular Modeling Studies of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors through 3D-QSAR and Molecular Docking Simulation , 2015 .

[50]  F. Uckun,et al.  Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* , 1999, The Journal of Biological Chemistry.

[51]  Ding Li,et al.  3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. , 2013, Journal of molecular graphics & modelling.

[52]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[53]  T. Kurosaki,et al.  Molecular mechanisms in B cell antigen receptor signaling. , 1997, Current opinion in immunology.

[54]  Rajendra Kumar,et al.  g_mmpbsa - A GROMACS Tool for High-Throughput MM-PBSA Calculations , 2014, J. Chem. Inf. Model..

[55]  Seung Joo Cho,et al.  Large variation in electrostatic contours upon addition of steric parameters and the effect of charge calculation schemes in CoMFA on mutagenicity of MX analogues , 2012 .

[56]  A. Sali,et al.  Statistical potentials for fold assessment , 2009 .

[57]  Seung Joo Cho,et al.  In silico study of 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl) ethanones derivatives as CCR1 antagonist: homology modeling, docking and 3D-QSAR approach. , 2014, Bioorganic & medicinal chemistry letters.

[58]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[59]  F. Uckun,et al.  Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.